key: cord-1001792-716comlu
authors: Kurup, Drishya; Myers, Jacob; Schnell, Matthias J.
title: Current vaccine strategies against SARS-CoV-2 - Promises and Challenges
date: 2022-05-23
journal: J Allergy Clin Immunol
DOI: 10.1016/j.jaci.2022.05.008
sha: 4ed614c04480bf62442dbd899a0d755f272ed446
doc_id: 1001792
cord_uid: 716comlu

In the years since the SARS-CoV-2 pandemic began and spread across the globe, lessons have been learned about the challenges and opportunities a pandemic brings to humankind. Researchers have produced many vaccines at unprecedented speed to protect people but have also been cognizant of the challenges presented by a new and unexpected infectious disease. The scope of this review is to examine the path of vaccine discovery so far and identify potential targets. Here we provide an insight into the leading vaccines and their advantages and challenges. We discuss the emerging mutations within the SARS CoV-2 Spike protein and other issues that need to be addressed to overcome COVID-19 completely. Future research is needed to develop a cheap, temperature-stable vaccine that provides long-term immunity that protects the upper respiratory tract.

Chimpanzee Ad (ChAd) 25

Receptor-binding domain (RBD) 27

Fc gamma Receptor and Transporter (FCGRT) 29

(2). While SARS CoV-1 was more pathogenic, SARS-CoV-2 has a higher reproductive number 48 (R0), indicating a much more efficient spread (3). Studies have suggested that while both viruses 49 bind to the angiotensin-converting enzyme 2 (ACE-2) receptor, the structural differences in the 50 surface Spike protein (S) of SARS CoV-2 enable a stronger binding to the ACE-2 receptor and 51 greater efficiency at invading host cell (4). Also, SARS CoV-2 yields lower neutralizing titers than 52 the SARS CoV-1 infection (5). Despite having proofreading capacity, SARS CoV-2 can 53 continuously evolve due to its high transmissibility and ability to evade the immune system, giving 54 rise to variants of concern like the Delta and Omicron strains. Thus, this evolving threat demands 55 that we focus on the challenges facing vaccine research.

The rampant early spread of SARS-CoV-2 made it evident that only an effective vaccine 57 would be able to control the pandemic. The perfect vaccine would be effective after a single 58 inoculation, easy to administer, stable at a wide range of temperatures and would prevent both 

The new mRNA technology can cause very unpleasant side effects which, while rarely 102 serious or long term, have soured a large portion of the population to such vaccines. The mild 103 side effects include pain, redness, or swelling at the site where the shot was administered, and/or 104 tiredness, headache, muscle pain, chills, fever, or nausea throughout the rest of the body; a few 105 rare but severe side effects such as anaphylaxis can also occur (13, 14) . Notably, there are 106 concerns regarding the long-term immunity of these mRNA vaccines, which require a booster 107 after 4-6 months(15). It is almost certain that such immunization strategies will fail based on the 108 low compliance rate observed for influenza vaccination, which requires only yearly boosters (16).

In addition to the mRNA and DNA vaccines, viral vector vaccines were also developed 

Initially, the replication-deficient vectors showed some promise, but the immune 125 responses were not as long-lived as envisioned. For example, waning immune responses were 126 detected as early as two months after vaccination with J&J/Janssen vaccine (2). While these 127 vaccines are still used in some countries, they are no longer used in the US. The widely-used 128 Oxford/Astra Zeneca vaccine is not recommended in several groups of people based on very rare 129 but severe side effects (fewer than 1 in 10,000 people). The severe side effects include immune 130 thrombosis associated with adenovirus vaccines, women developing menstrual problems, 131 capillary leak syndrome, and heart inflammation (13, 18) . Despite these vaccine associated side-132 effects, observational cohort studies of COVID-19 patients after discharge reported symptoms 133 such as fatigue and dyspnea (39%), sleep disturbance (24%), chest pain (12%), and cough 134 (11%), had a readmission rate of 15% and a mortality rate of 6.7% (19) , suggesting SARS-CoV- generously funded (e.g., 1.6 billion dollars for Novavax). Additionally, "deactivated" or "killed" 146 vaccines have a long history of safety and long-term efficacy, which can be lifelong. These 147 platforms have provided some encouraging clinical and/or preliminary results, have minor side 148 effects, and are likely to be more acceptable by a larger section of the population because they 149 have been successfully used previously for other vaccines. Whereas the "killed" vaccines provide 150 better temperature stability, they yet to need to provide evidence for: 1) manufacturing scalability, 151 2) long-term stability at 2-8ºC, and 3) long-term immunity without requiring regularly boosting. 

We know that variants will continue to emerge, including those with a high mutation rate, 183 which may or may not be controlled by the current vaccines. As with many topics regarding 184 COVID-19, we can only speculate what will happen in the future. The good news is that many of 185 the mutants of SARS-CoV-2 did not spread as much as we anticipated and mostly showed people with preexisting immunity. Therefore, preexisting immunity might be another concern for 214 viral vectors. Several intranasal vaccines are now being tested in clinical trials (43).

The need for additional booster shots has also driven researchers' efforts to develop a 216 pan-coronavirus vaccine, based on the influenza vaccine model, which may mean annual shots.

The coronavirus family is a subfamily of orthocoronaviruses, and there are 4 different genera 218 within the subfamily: alphacoronavirus (infects all mammals, including humans, causing cold-type 219 symptoms, most-likely have bat origins; betacoranavirus (MERS, SARS, and SARS-CoV-2); 220 gammacoronaviruses; and deltacoronaviruses (derived from ancestors in pigs and bird species).

The betacoronaviruses have several sublineages: Embecoviruses (lineage A; some of the 

In summary, many vaccines against COVID-19 are available but none are perfect. The 228 goal of vaccination is to decrease infections, hospitalizations, and mortality. Thus far, the perfect 229 candidate, one that is cheap, temperature stable, and provides long-term immunity, including in 230 the upper respiratory tract, has yet to be found.

J o u r n a l P r e -p r o o f 

COVID-19) Dashboard

SARS-CoV-2 vaccines -the biggest medical research project of the 234 21st century

Comparing SARS-CoV-2 with SARS-CoV 236 and influenza pandemics

SARS-CoV-2 spike binding 238 to ACE2 is stronger and longer ranged due to glycan interaction

Serological differentiation 240 between COVID-19 and SARS infections

Current advances in the development of SARS-242

CoV-2 vaccines

World Health Organization. COVID-19 vaccine tracker and landscape

Vaccine-247 associated enhanced disease: Case definition and guidelines for data collection, analysis, and 248 presentation of immunization safety data

Texas Children's Hospital and Baylor College of Medicine COVID-19 Vaccine 250 Technology Secures Emergency Use Authorization in India

The tangled history of mRNA vaccines

Our World in Data. Coronavirus (COVID-19) Vaccinations. Accessed on

Comparing the COVID-19 Vaccines: How Are They 259 Different? MARCH 30

Vaccine Type and Adverse Effects Following Vaccination

Effectiveness 265 of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the 266 USA: a retrospective cohort study

Barriers of Influenza Vaccination 268 Intention and Behavior -A Systematic Review of Influenza Vaccine Hesitancy

Adenoviral vector vaccine platforms in the 271 SARS-CoV-2 pandemic

Coagulopathies after Vaccination against SARS-CoV-2 May Be Derived from a 273 Combined Effect of SARS-CoV-2 Spike Protein and Adenovirus Vector-Triggered Signaling 274 Pathways

Post Acute Coronavirus (COVID-19) Syndrome. StatPearls. 276 Treasure Island (FL)

Safety and 278 immunogenicity of the measles vector-based SARS-CoV-2 vaccine candidate

Merck Discontinues Development of SARS-CoV-2/COVID-19 Vaccine Candidates

Continues Development of Two Investigational Therapeutic Candidates

SARS-CoV-2 vaccines 287 strategies: a comprehensive review of phase 3 candidates

Inactivated 289 rabies virus vectored SARS-CoV-2 vaccine prevents disease in a Syrian hamster model

Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed 293 Individuals

SARS-CoV-2-specific antibody and T-295 cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort 296 study

T cell responses to 298 SARS-CoV-2 spike cross-recognize Omicron

Omicron escapes the majority of 300 existing SARS-CoV-2 neutralizing antibodies

SARS-CoV-2 501Y.V2 variants lack higher 302 infectivity but do have immune escape

CoV-2 mutational profile, spike protein stability and viral transmission

Antibody titers and breakthrough infections with Omicron SARS-CoV-2

Occurrence 310 and significance of Omicron BA.1 infection followed by BA.2 reinfection

CoV-2 Omicron BA.1 and BA.2 Variants

Significantly Increased Vaccine Breakthrough, Decreased Hospitalization Rates, and Less Severe 316

Disease in Patients with Coronavirus Disease 2019 Caused by the Omicron Variant of Severe 317

Acute Respiratory Syndrome Coronavirus 2 in Houston, Texas. The American Journal of 318 Pathology

The severity of the 320 first 207 infections with the SARS-CoV-2 Omicron BA.2 variant

Previous Infection Combined 325 with Vaccination Produces Neutralizing Antibodies with Potency against SARS-CoV-2 Variants. 326 mBio

Vaccines over a 9-Month Period in North Carolina

Covid-19 Vaccine 330 Effectiveness against the Omicron (B.1.1.529) Variant

Intranasal priming induces 332 local lung-resident B cell populations that secrete protective mucosal antiviral IgA

A single 335 intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 336 infection in rhesus macaques

Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2

Unadjuvanted 341 intranasal spike vaccine booster elicits robust protective mucosal immunity against 342 sarbecoviruses. bioRxiv. 2022. 343 43. NIH. Clinical trials. COVID-19 intranasal vaccine

Pan-coronavirus vaccine pipeline takes form